References
- Hellstrom K E, Hellstrom I. Cellular immunity against tumor antigens. Adv Cancer Res 1969; 12: 167–223
- Howell S B, Dean H J, Law L W. Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer 1975; 15: 152–179
- Friedman H, Spectra S, Kamo I, Kateley J. Tumor associated immunosuppressive factors. Ann NY Acad Sci 1976; 276: 417–430
- Hellstrom K E, Hellstrom I. Lymphocyte mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 1974; 18: 209–275
- Fujimoto S, Greene M I, Sehon A H. Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J Immunol 1976; 116: 800–806
- Eisen H N, Sakoto N, Hall S J. Myeloma proteins as specific antigens. Transplant Proc 1975; 7: 209–214
- Williams W H, Krueger R G. Tumor associated transplantation antigens of myelomas induced in BALB/c mice. J Natl Cancer Inst 1972; 49: 1613–1620
- Poupon M F, Lespinats G. Cell mediated immunity directed against a syngeneic plasma cell tumor in the mouse. Determination by macrophage migration inhibition test. J Natl Cancer Inst 1972; 48: 1297–1301
- Abbas A L. T-lymphocyte-mediated suppression of myeloma function in vitro. I. Suppression by allogeneically activated T-lymphocyte. J. Immunol 1979; 123: 2011–2018
- Lubet R A, Carlson D E. Tumor immunity against MOPC 104E. Leukocyte adherence inhibition (L.A.I.) assay. Eur J Cancer 1980; 16: 687–694
- Wang K C, Berczi I, Hoffmann E G, Sehon A H. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice II. Dynamic changes during tumor regression. Int J Cancer 1980; 25: 493–501
- Ghanta V K, Hiramoto R N, Davis D W, Hiramoto N S. Maintenance of MOPC 104E myeloma in plateau phase. Cancer Res 1980; 40: 2372–2376
- Ghanta V K, Cox P J, Hiramoto N S, et al. Host regulation of MOPC 104E plasmacytoma after reduction of tumor burden by total body irradiation. Cancer Invest 1985; 3(3)217–223
- Burton R, Thompson J, Warner N L. In vitro induction of tumor-specific immunity. J Immunol Meth 1975; 8: 133–150
- Julius H M, Simpson E, Herzenberg L A. A rapid method of isolation of functional thymus-derived muring lymphocytes. Eur J Immunol 1973; 3: 645–649
- McCoy J L, Dean J H, Law L W, et al. Immunogenicity, antigenicity and mechanisms of tumor rejection of mineral oil-induced plasmacytomas in syngeneic BALB/c mice. Int J Cancer 1974; 14: 264–276
- Burton R C, Warner H L. Tumor immunity to murine plasma cell tumors V. Genetic control of the in vitro cytotoxic T-cell response to plasma cell tumor-associated antigens of NZB mice. J Natl Cancer Inst 1980; 65: 431–440
- Boye P JJ, Fahey J L. Stimulation of lymphoid cells from normal and immune mice by syngeneic BALB/c plasma cell tumors. J Immunol 1976; 116: 202–209
- Chen Y-H, Anderson A B, Williams K G. Splenic immune effector and suppressor cells in mice bearing a growing plasmacytoma. Cancer Res 1985; 45: 473–5479
- Herberman R B, Aoki T. Immune and natural antibodies to syngeneic murine plasma cell tumors. J Exp Med 1972; 136: 94–111
- Small M, Trainin N. Separation of populations of sensitized lymphoid cells into fractions inhibiting and fractions enhancing syngeneic tumor growth in vivo. J Immunol 1976; 117: 292–297
- Tse H Y, Dutton R W. Separation of helper and suppressor T-lymphocytes III. Positive and negative effects of mixed lymphocyte reaction activated T-cells. J Immunol 1978; 120: 1149–1152
- Bresnihan Jasin E. H. Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus. J Clin Invest 1977; 59: 106–116
- Stobo J D, Paul S., Van, Scoy R E, Hermans P E. Suppressor thymus-derived lymphocytes in fungal infection. J Clin Invest 1976; 57: 319–328
- Miura T., Hayashida I, Ghanta V K, et al. Regulation and/or regression of MOPC 104E induced in vivo is not due to cytotoxic T-lymphocytes. Fed Proc 1983; 1197
- Shu S, Rosenberg S A. Adoptive immunotherapy of a newly induced sarcoma: Immunologic characteristics of effector cells. J Immunol 1985; 135: 2895–2903